Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 12, Number 10—October 2006

Dispatch

Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa

Zhiquan Xiang*, Yan Li*, Ann Cun*, Wei Yang†, Susan Ellenberg†, William M. Switzer‡, Marcia L. Kalish‡, and Hildegund C.J. Ertl*Comments to Author 
Author affiliations: *The Wistar Institute, Philadelphia, Pennsylvania, USA; †University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; ‡Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure

Prevalence of neutralizing antibody titers to chimpanzee adenoviruses. Percentages of negative samples are not shown. Left column: Cameroon, black bars; Côte d'Ivoire, white bars; Nigeria: gray bars. Middle column: Thailand, black bars; US controls, white bars; US zoo keepers or animal handlers, gray bars. VNAs, virus neutralizing antibodies. Coded human serum samples that had been collected for other studies were obtained under an institutional review board exemption.

Figure. Prevalence of neutralizing antibody titers to chimpanzee adenoviruses. Percentages of negative samples are not shown. Left column: Cameroon, black bars; Côte d'Ivoire, white bars; Nigeria: gray bars. Middle column: Thailand, black bars; US controls, white bars; US zoo keepers or animal handlers, gray bars. VNAs, virus neutralizing antibodies. Coded human serum samples that had been collected for other studies were obtained under an institutional review board exemption.

Main Article

TOP